This menu provides the list of EV proteins identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Protein name UniProt accession Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Quantitative proteomics of extracellular vesicles released from human monocyte-derived macrophages upon beta-glucan stimulation.
J Proteome Res. 2014 May 2;13(5):2468-77. doi: 10.1021/pr4012552. Epub 2014 Apr 16.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.
Proteomics. 2014 Jun;14(12):1472-9. doi: 10.1002/pmic.201300485. Epub 2014 May 15.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
J Proteomics. 2014 Jun 25;106:191-204. doi: 10.1016/j.jprot.2014.04.028. Epub 2014 Apr 24.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung Endothelial Microparticle Shedding.
Am J Respir Cell Mol Biol. 2014 Jul 16.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung Endothelial Microparticle Shedding.
Am J Respir Cell Mol Biol. 2014 Jul 16.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung Endothelial Microparticle Shedding.
Am J Respir Cell Mol Biol. 2014 Jul 16.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Pathologic Mechanical Stress and Endotoxin Exposure Increases Lung Endothelial Microparticle Shedding.
Am J Respir Cell Mol Biol. 2014 Jul 16.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro.
Biochim Biophys Acta. 2014 Nov;1838(11):2954-65. doi: 10.1016/j.bbamem.2014.07.026. Epub 2014 Aug 4.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro.
Biochim Biophys Acta. 2014 Nov;1838(11):2954-65. doi: 10.1016/j.bbamem.2014.07.026. Epub 2014 Aug 4.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Extravillous trophoblast cells-derived exosomes promote vascular smooth muscle cell migration.
Front Pharmacol. 2014 Aug 11;5:175. doi: 10.3389/fphar.2014.00175. eCollection 2014.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Antibody-coupled monolithic silica microtips for highthroughput molecular profiling of circulating exosomes.
Sci Rep. 2014 Aug 29;4:6232. doi: 10.1038/srep06232.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS.
J Proteome Res. 2014 Oct 8.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Lipidomic and proteomic characterization of platelet extracellular vesicle subfractions from senescent platelets.
Transfusion. 2014 Oct 21. doi: 10.1111/trf.12874.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Lipidomic and proteomic characterization of platelet extracellular vesicle subfractions from senescent platelets.
Transfusion. 2014 Oct 21. doi: 10.1111/trf.12874.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758A New Workflow for Proteomic Analysis of Urinary Exosomes and Assessment in Cystinuria Patients.
J Proteome Res. 2014 Nov 12.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758A New Workflow for Proteomic Analysis of Urinary Exosomes and Assessment in Cystinuria Patients.
J Proteome Res. 2014 Nov 12.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic analysis of human placental syncytiotrophoblast microvesicles in preeclampsia.
Clin Proteomics. 2014 Nov 19;11(1):40. eCollection 2014.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Intraluminal proteome and peptidome of human urinary extracellular vesicles.
Proteomics Clin Appl. 2014 Dec 4. doi: 10.1002/prca.201400085.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Vascular Smooth Muscle Cell Calcification is Mediated by Regulated Exosome Secretion.
Circ Res. 2015 Feb 23. pii: CIRCRESAHA.114.305012.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Urinary extracellular vesicles as reservoirs of altered proteins during the pathogenesis of polycystic kidney disease.
Proteomics Clin Appl. 2015 Mar 9. doi: 10.1002/prca.201400199.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Human thymic epithelial primary cells produce exosomes carrying tissue-restricted antigens.
Immunol Cell Biol. 2015 Mar 17. doi: 10.1038/icb.2015.33.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosomes released from breast cancer carcinomas stimulate cell movement.
PLoS One. 2015 Mar 23;10(3):e0117495. doi: 10.1371/journal.pone.0117495. eCollection 2015.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Oncotarget. 2015 Mar 12.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Oncotarget. 2015 Mar 12.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Highly-purified exosomes and shed microvesicles isolated from the human colon cancer cell line LIM1863 by sequential centrifugal ultrafiltration are biochemically and functionally distinct.
Methods. 2015 Apr 16. pii: S1046-2023(15)00154-1. doi: 10.1016/j.ymeth.2015.04.008.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Highly-purified exosomes and shed microvesicles isolated from the human colon cancer cell line LIM1863 by sequential centrifugal ultrafiltration are biochemically and functionally distinct.
Methods. 2015 Apr 16. pii: S1046-2023(15)00154-1. doi: 10.1016/j.ymeth.2015.04.008.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Highly-purified exosomes and shed microvesicles isolated from the human colon cancer cell line LIM1863 by sequential centrifugal ultrafiltration are biochemically and functionally distinct.
Methods. 2015 Apr 16. pii: S1046-2023(15)00154-1. doi: 10.1016/j.ymeth.2015.04.008.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes.
Oncotarget. 2015 Apr 12.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes.
Oncotarget. 2015 Apr 12.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines.
Pigment Cell Melanoma Res. 2015 May 7. doi: 10.1111/pcmr.12380.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines.
Pigment Cell Melanoma Res. 2015 May 7. doi: 10.1111/pcmr.12380.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines.
Pigment Cell Melanoma Res. 2015 May 7. doi: 10.1111/pcmr.12380.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines.
Pigment Cell Melanoma Res. 2015 May 7. doi: 10.1111/pcmr.12380.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines.
Pigment Cell Melanoma Res. 2015 May 7. doi: 10.1111/pcmr.12380.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines.
Pigment Cell Melanoma Res. 2015 May 7. doi: 10.1111/pcmr.12380.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines.
Pigment Cell Melanoma Res. 2015 May 7. doi: 10.1111/pcmr.12380.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosome enrichment of human serum using multiple cycles of centrifugation.
Electrophoresis. 2015 May 23. doi: 10.1002/elps.201500131.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosome enrichment of human serum using multiple cycles of centrifugation.
Electrophoresis. 2015 May 23. doi: 10.1002/elps.201500131.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15.
Proteomics. 2015 Jun 2. doi: 10.1002/pmic.201400610.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15.
Proteomics. 2015 Jun 2. doi: 10.1002/pmic.201400610.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15.
Proteomics. 2015 Jun 2. doi: 10.1002/pmic.201400610.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15.
Proteomics. 2015 Jun 2. doi: 10.1002/pmic.201400610.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Ionizing radiation affects protein composition of exosomes secreted in vitro from head and neck squamous cell carcinoma.
Acta Biochim Pol. 2015;62(2):265-72. doi: 10.18388/abp.2015_970. Epub 2015 Jun 22.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.
Blood. 2015 Jun 22. pii: blood-2014-12-618025.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.
Blood. 2015 Jun 22. pii: blood-2014-12-618025.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.
Blood. 2015 Jun 22. pii: blood-2014-12-618025.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.
Blood. 2015 Jun 22. pii: blood-2014-12-618025.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosomes released by keratinocytes modulate melanocyte pigmentation.
Nat Commun. 2015 Jun 24;6:7506. doi: 10.1038/ncomms8506.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
Nature. 2015 Jun 24. doi: 10.1038/nature14581.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Glypican-1 identifies cancer exosomes and detects early pancreatic cancer.
Nature. 2015 Jun 24. doi: 10.1038/nature14581.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Extracellular vesicles are rapidly purified from human plasma by PRotein Organic Solvent PRecipitation (PROSPR).
Sci Rep. 2015 Sep 30;5:14664. doi: 10.1038/srep14664.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Osteoblast-released matrix vesicles - regulation of activity and composition by sulfated and non-sulfated glycosaminoglycans.
Mol Cell Proteomics. 2015 Nov 23. pii: mcp.M115.049718.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Osteoblast-released matrix vesicles - regulation of activity and composition by sulfated and non-sulfated glycosaminoglycans.
Mol Cell Proteomics. 2015 Nov 23. pii: mcp.M115.049718.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Osteoblast-released matrix vesicles - regulation of activity and composition by sulfated and non-sulfated glycosaminoglycans.
Mol Cell Proteomics. 2015 Nov 23. pii: mcp.M115.049718.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Osteoblast-released matrix vesicles - regulation of activity and composition by sulfated and non-sulfated glycosaminoglycans.
Mol Cell Proteomics. 2015 Nov 23. pii: mcp.M115.049718.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Identification of developmental endothelial locus-1 on circulating extracellular vesicles as a novel biomarker for early breast cancer detection.
Clin Cancer Res. 2015 Nov 24. pii: clincanres.0654.2015.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Commitment of Annexin A2 in recruitment of microRNAs into extracellular vesicles.
FEBS Lett. 2015 Nov 26. pii: S0014-5793(15)01049-2. doi: 10.1016/j.febslet.2015.11.036.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Commitment of Annexin A2 in recruitment of microRNAs into extracellular vesicles.
FEBS Lett. 2015 Nov 26. pii: S0014-5793(15)01049-2. doi: 10.1016/j.febslet.2015.11.036.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.
J Proteomics. 2015 Dec 28. pii: S1874-3919(15)30222-0. doi: 10.1016/j.jprot.2015.12.023.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.
J Proteomics. 2015 Dec 28. pii: S1874-3919(15)30222-0. doi: 10.1016/j.jprot.2015.12.023.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.
J Proteomics. 2015 Dec 28. pii: S1874-3919(15)30222-0. doi: 10.1016/j.jprot.2015.12.023.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
J Proteomics. 2016 Jan 13. pii: S1874-3919(15)30214-1. doi: 10.1016/j.jprot.2015.12.016.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
J Proteomics. 2016 Jan 13. pii: S1874-3919(15)30214-1. doi: 10.1016/j.jprot.2015.12.016.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
J Proteomics. 2016 Jan 13. pii: S1874-3919(15)30214-1. doi: 10.1016/j.jprot.2015.12.016.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.
J Proteomics. 2016 Jan 13. pii: S1874-3919(15)30214-1. doi: 10.1016/j.jprot.2015.12.016.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Circular RNAs co-precipitate with extracellular vesicles: a possible mechanism for circRNA clearance.
PLoS One. 2016 Feb 5;11(2):e0148407. doi: 10.1371/journal.pone.0148407. eCollection 2016.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Fibronectin-Containing Extracellular Vesicles Protect Melanocytes Against Ultraviolet Radiation-Induced Cytotoxicity.
J Invest Dermatol. 2016 Feb 5. pii: S0022-202X(16)00461-9. doi: 10.1016/j.jid.2015.08.001.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201521230.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201521230.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201521230.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201521230.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis.
Int J Clin Exp Pathol. 2015 Dec 1;8(12):15719-28. eCollection 2015.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis.
Int J Clin Exp Pathol. 2015 Dec 1;8(12):15719-28. eCollection 2015.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA.
J Extracell Vesicles. 2016 Feb 24;5:29828. doi: 10.3402/jev.v5.29828. eCollection 2016.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA.
J Extracell Vesicles. 2016 Feb 24;5:29828. doi: 10.3402/jev.v5.29828. eCollection 2016.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758ExtraPEG: a polyethylene glycol-based method for enrichment of extracellular vesicles.
Sci Rep. 2016 Apr 12;6:23978. doi: 10.1038/srep23978.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein.
Oncotarget. 2016 Apr 11. doi: 10.18632/oncotarget.8678.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein.
Oncotarget. 2016 Apr 11. doi: 10.18632/oncotarget.8678.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Facile preparation of salivary extracellular vesicles for cancer proteomics.
Sci Rep. 2016 Apr 19;6:24669. doi: 10.1038/srep24669.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Enrichment of extracellular vesicles from tissues of the central nervous system by PROSPR.
Mol Neurodegener. 2016 May 23;11(1):41. doi: 10.1186/s13024-016-0108-1.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Effective isolation of exosomes with polyethylene glycol from cell culture supernatant for in-depth proteome profiling.
Analyst. 2016 May 27.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic Analysis of Exosomes and Exosome-Free Conditioned Media Derived from Human Osteosarcoma Cell Lines Reveal Differential Secretion of Proteins Related to Biological Functions and Tumor Progression.
J Cell Biochem. 2016 Jun 30. doi: 10.1002/jcb.25642.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic Analysis of Exosomes and Exosome-Free Conditioned Media Derived from Human Osteosarcoma Cell Lines Reveal Differential Secretion of Proteins Related to Biological Functions and Tumor Progression.
J Cell Biochem. 2016 Jun 30. doi: 10.1002/jcb.25642.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Proteomic Analysis of Exosomes and Exosome-Free Conditioned Media Derived from Human Osteosarcoma Cell Lines Reveal Differential Secretion of Proteins Related to Biological Functions and Tumor Progression.
J Cell Biochem. 2016 Jun 30. doi: 10.1002/jcb.25642.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility.
Oncotarget. 2016 Jun 27. doi: 10.18632/oncotarget.10307.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.
Oncotarget. 2016 Aug 8. doi: 10.18632/oncotarget.11111.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.
Oncotarget. 2016 Aug 8. doi: 10.18632/oncotarget.11111.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.
Oncotarget. 2016 Aug 8. doi: 10.18632/oncotarget.11111.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.
Oncotarget. 2016 Aug 8. doi: 10.18632/oncotarget.11111.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Efficient production and enhanced tumor delivery of engineered extracellular vesicles.
Biomaterials. 2016 Jul 6;105:195-205. doi: 10.1016/j.biomaterials.2016.07.003.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Efficient production and enhanced tumor delivery of engineered extracellular vesicles.
Biomaterials. 2016 Jul 6;105:195-205. doi: 10.1016/j.biomaterials.2016.07.003.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.
Sci Rep. 2016 Sep 8;6:32643. doi: 10.1038/srep32643.		ENOG410XPUN542 / 0 / 542
Annexin A5 (Anchorin CII) (Annexin V) (Annexin-5) (Calphobindin I) (CBP-I) (Endonexin II) (Lipocortin V) (Placental anticoagulant protein 4) (PP4) (Placental anticoagulant protein I) (PAP-I) (Thromboplastin inhibitor) (Vascular anticoagulant-alpha) (VAC-alpha)P08758Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.
Sci Rep. 2016 Sep 8;6:32643. doi: 10.1038/srep32643.		ENOG410XPUN542 / 0 / 542
< [2] [3] [4]